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Growing evidence suggests that Alzheimer disease (AD) origins in vascular lesions. As the crucial
mediator of vascular pathology, angiotensin II-induced signiﬁcant amyloid production in our labo-
ratory, although amyloid neurotoxicity depended on phosphorylated tau (p-tau) in recent studies. In
the present study, p-tau levels were signiﬁcantly elevated by central angiotensin II via glycogen syn-
thase kinase 3b (GSK 3b) and other tau kinases. Moreover, angiotensin II-induced cognitive impair-
ment and tau phosphorylation was attenuated by losartan and a GSK 3b inhibitor. These ﬁndings
implicate Ang II as a crucial mediator of AD pathology and a link between cardiovascular events
and AD.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Alzheimer disease (AD) is one of the most important unmet
needs in neurology, with oligomer-prone b-amyloid (Ab) and phos-
phorylated tau (p-tau) as its pathological hallmarks [1]. Glycogen
synthase kinase 3b (GSK 3b), the main tau kinase, are thus also in-
volved in AD pathogenesis. More recently, growing evidence has
indicated that AD is initiated by vascular factors that precede the
neurodegenerative process, leading to AD being termed a vascular
disorder [2].
As an intrinsic vasoactive hormone and the main actor in the
renin–angiotensin system (RAS), brain angiotensin II (Ang II) is
always present in abnormally high quantities in many cardiovascu-
lar diseases [3]. More recently, it has also been implicated in AD
[4,5]. Excess Ang II was linked to increased blood pressure,
decreased cerebrovascular compliance and enhanced brain
inﬂammation, all recognized risk factors for AD, while Ang II type
1 receptor (AT1R) blockade suppressed such processes [6,7]. More-
over, application of AT1R blockers to rodents led to attenuated
neurotoxic accumulation and cognitive deﬁcits [8–12]. In our
laboratory, central infusion of Ang II signiﬁcantly promoted Ab
production via enhanced amyloidogenic processing [13]. These
ﬁndings implicated Ang II as a crucial mediator in AD, just as it
has been implicated in cardiovascular pathology [14].chemical Societies. Published by EHowever, Ab plaques correlate poorly with cognition decline
[15] and plaque removal did not prevent neurodegeneration [16],
suggesting that other entities may be required for Ab-induced
neurotoxicity. As noted in AD rodent models, the presence of tau
is required for Ab-induced neuronal and synaptic damage [1].
Reducing endogenous tau ameliorates Ab-induced neuronal dys-
function [17], while dendritic function of tau mediates Ab-associ-
ated synaptotoxicity [18]. In older individuals at risk for
dementia, Ab-associated brain volume loss and longitudinal clini-
cal decline occurs only in the presence of p-tau [19,20]. It thus
has been proposed that Ab neurotoxicity is dependent on tau, espe-
cially p-tau. It is therefore intriguing to determine the levels of p-
tau in response to Ang II stimulation, because our ﬁndings have
conﬁrmed that Ang II could induce Ab production.
In the present study, graded doses of Ang II were delivered into
rat brain ventricles via osmotic pumps, as a model of increased
brain Ang II in vascular-related events. The levels of AD-like p-
tau were then assayed and the signaling pathways involved were
also uncovered.
2. Materials and methods
2.1. Animals and groups
Male Sprague–Dawley (SD) rats, Wistar-Kyoto (WKY) rats and
spontaneously hypertensive rats (SHR) were obtained from the
Shanghai branch of the National Rodent Laboratory Animal Re-
sources of China and housed under standard environmentallsevier B.V. All rights reserved.
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light/dark cycle with lights on at 6:00 am; and ad libitum access
to food and water). Two months old (280–310 g) was qualiﬁed
for these experiments. Animal care and experiment protocols were
carried out with adherence to the Guide for the Care and Use of
Laboratory Animals of Nanjing Medical University and were ap-
proved by the Biological Research Ethics Committee of Nanjing
Medical University. All surgeries were performed with the aim of
limiting the animals’ suffering.
To investigate the effects of central Ang II on tau phosphoryla-
tion, SD rats (n = 12) were intracerebroventricularly subjected to
denaturized Ang II (24 ng/ll, the control group), low-dose Ang II
(24 ng/ll, Sigma, Germany), medium-dose Ang II (240 ng/ll),
high-dose Ang II (2400 ng/ll), medium-dose Ang II + losartan
(800 ng/ll), or losartan (800 ng/ll, Sigma, Germany).
To investigate the effects of blood pressure on GSK 3b activa-
tion, SHR (n = 12) were administrated Propranolol hydrochloride
(50 mg/kg or 100 mg/kg, Sigma, Germany) orally with a gastric
tube once daily for 1 week, while SHR control and WKY rats were
administrated saline (1 ml/kg) in the same way.
To investigate the effects of GSK 3b inhibition on tau phosphor-
ylation, SD rats (n = 12) were intracerebroventricularly subjected
to: denaturized Ang II, high-dose Ang II, high-dose Ang II + SB
(SB216763, 20 ng/ll, a highly selective and cell permeable GSK3
inhibitor, Sigma, Germany) or SB (20 ng/ll).
Because the pumps work at a rate of 0.25 ll/h, the actual doses
delivered into rat brains were actually 1/4 of those mentioned
above (about 1.67, 16.7, and 167 pg/s, respectively for Ang II).
Moreover, the high dose was arbitrarily chosen to be approxi-
mately one tenth of the highest dose reported by Porter et al. [21].
Systolic blood pressure (SBP) was measured between 08:00 and
12:00 am on day 0 (pre-surgery), day 3, day 5 and day 7 in SD rats
and before sacriﬁce in SHR and WKY rats. The assays of Morris
water maze were performed between 02:00 and 06:00 pm on
day 4–7. Then, all animals were sacriﬁced and the hippocampi
were removed. Hippocampal Ang II contents, p-tau levels and
GSK3b activities were then assayed.
In our preliminary experiments, 800 ng/ll losartan could com-
pletely cancel the pressor effects of 240 ng/ll Ang II and denatural-
ized Ang II infusion was not accompanied with alteration in SBP.
2.2. Blood pressure measurements
In the present study, SBP was measured by the tail cuff method
using a non-invasive blood pressure analyzer (BP-2000, Visitech
Systems, Inc., Apex, NC, USA). Seven days prior to treatment, SBP
was measured to make sure that animals were acclimated to the
BP-2000 Blood Pressure System. Then, measurements were per-
formed on day 0 (before surgery), day 3 (three days after surgery),
day 5 (ﬁve days after surgery) and day 7 (seven days after surgery)
in SD rats and before sacriﬁce in SHR between 08:00 and 12:00 am.
Each measurement was performed 10 times to acquire a mean SBP.
2.3. Intracerebroventricular infusion
After one-week of house acclimation, AD rats were subjected to
unilateral intracerebroventricular (ICV) infusion via osmotic
pumps (Alzet, model 2004, CA, USA) for another one-week. The
pumps were incubated in sterile saline at 37 C for at least 40 h be-
fore they were implanted into animals.
ICV implantation was performed following procedures well-
established in our laboratory [13]. Brieﬂy, after being anesthetized
with 10% chloral hydrate (0.35 ml/100 g, Amresco, OH, USA), rats
were placed in a stereotactic frame (David Kopf, CA, USA). Stainless
steel cannulas from the brain infusion kit were stereotaxically im-
planted in the right lateral ventricle of the brain (anteroposterior,0.8 mm; dorsoventral, 3.5 mm; mediolateral, 1.4 mm from bregma
as a reference). The pumps were then implanted subcutaneously
on the backs of the rats.
2.4. Morris water maze
Cognitive and behavioral performances of all rats were assayed
by Morris water maze. The protocols were published anywhere.
Brieﬂy, a circular pool, 150 cm in diameter, was ﬁlled up with
tap water and maintained at 22 ± 1 C. The escape platform
(15 cm in diameter) was placed in the pool so that it was sub-
merged 2 cm below the water surface. Each rat was given four tri-
als per day over three consecutive days (day 4, 5 and 6). For each
trial, the rat was placed in the pool (facing pool wall) at one of four
selected starting points (North, South, East or West pole). On locat-
ing the platform, the rat was allowed to remain there for 30 s be-
fore being returned to its cage. If the rat did not ﬁnd the
platform within 120 s, the time was recorded as 120 s. Then, the
rat was guided to the platform by hand and allowed to remain
there for 30 s. The escape latency and swim speed were measured
by a video tracking system for the analysis of performance. After
the last training trial, rats were subjected to a probe trial in which
the platform was removed. Animals were placed in the pool at the
same pole and allowed to swim for 2 min. The time that each ani-
mal spent in the quadrant that had previously contained the hid-
den platform was recorded.
2.5. Enzyme immunoassays (EIAs) for hippocampal Ang II
Ang II levels in rat brain extracts were measured using commer-
cial EIA kits (Bachem, Switherland). Brieﬂy, hippocampus was dis-
sected and homogenized in 5 ml/g lysis buffer (10 mM Tris, pH
7.4). After mixing and centrifugation (1,600g for 15 min at
4 C), the supernatant was loaded on an equilibrated SEP-Pak C18
cartridge (Millipore, CA, USA). Equilibration was performed by
washing once with 1 ml of buffer B (60% acetonitrile in 1% triﬂuo-
roacetic acid) and three times with 3 ml of buffer A (1% triﬂuoro-
acetic acid). Peptides were eluted with 3 ml of buffer B and
collected in a 15-ml polystyrol tube, evaporated to dryness, and
the residue was dissolved in 250 ll of EIA buffer. For EIA, 50 ll of
each sample was used. All samples were analyzed in duplicate.
Concentrations are expressed in pg per 1 g of brain tissue.
2.6. Western blotting
The hippocampi were homogenized in ice-cold lysis buffer con-
sisting of 50 mmol/l Tris–HCl, 150 mmol/l sodium chloride, 1% Tri-
ton X-100, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate,
protease inhibitors phenylmethylsulfonyl ﬂuoride (Sigma) and a
phosphatase inhibitor cocktail (Roche, Switzerland) using an ultra-
sound homogenizer (IKA Laboratory, NC, USA). Tissue homoge-
nates were then centrifuged for 15 min at 12,000 rpm at 4 C
(Beckman, CA, USA). Supernatants were carefully collected. Protein
concentrations were determined using the Bradford method and
were stored at 80 C until analysis.
Equal amounts of protein (about 60 lg) were electrophoresed
on 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis
and transferred onto polyvinylidene diﬂuoride membranes (Milli-
pore). After blocking with buffer containing 50 mmol/l Tris–HCl,
pH 7.4, 200 mmol/l sodium chloride and 0.5 mmol/l Tween 20
(TBST buffer) and 5% non-fat milk powder, the membranes were
incubated overnight at 4 C with primary antibodies (Table 1) in
blocking buffer. Then, after washing in several volumes TBST buf-
fer, the blots were incubated with anti-mouse or anti-rabbit horse-
radish peroxidase-conjugated secondary antibodies in TBST buffer
mixed with 10% non-fat dried milk. The blots were then soaked in
Table 1
Characteristics of antibodies.
Antibody Type Speciﬁcity Phosphorylation sites Reference/source
Tau-5 Mono- Tau Invitrogen
pSer396 Poly- p-tau Ser396 Santa Cruz
pSer404 Poly- p-tau Ser235 Santa Cruz
pSer356 Poly- p-tau Ser356 Santa Cruz
pSer235 Poly- p-tau Thr231 Santa Cruz
pThr205 Poly- p-tau Ser404 Santa Cruz
pThr231 Poly- p-tau Thr205 Santa Cruz
GSK3 Mono- GSK3 Abcam
pGSK3b Poly- P-GSK3b Tyr216 Santa Cruz
Fig. 1. Effects of central Ang II or SB on SBP in rats. The alterations of SBP by Ang II
(A), losartan (A) and SB (B) was tracked by the tail cuff method. Measurements were
performed on day 0 (before surgery), day 3 (three days after surgery), day 5 (ﬁve
days after surgery) and day 7 (seven days after surgery). Each measurement was
performed 10 times to acquire a mean SBP. All results are presented as mean ± S.D.,
n = 12 for each group, ⁄P < 0.05 or ⁄⁄P < 0.01 versus the control rats. ++P < 0.01 the
high-dose AngII + SB group versus the control group.
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posed to ﬁlms (Kodak, Japan) for various periods of time (0.05–
5 min). The blots were then incubated with 30% (w/v) hydrogen
peroxide for 15 min at 37 C, reblocked, and reprobed with other
antibodies.
Intensities from X-ray ﬁlm were quantiﬁed using Densitometer
Quantity One software (Bio-Rad, CA, USA) after ascertaining
linearity.
2.7. Enzyme-linked immunosorbent assay (ELISA) for Ab
For Ab concentration assays, tissue extracts were prepared as
described by us [13]. Brieﬂy, hippocampus were homogenized in
10 volumes of high-salt buffer (100 mmol/l Tris–HCl, pH 7.0,
1 mmol/l EGTA, 0.5 mmol/l magnesium sulfate, 750 mmol/l so-
dium chloride, 20 mmol/l sodium ﬂuoride) containing protease
inhibitors (Sigma). Soluble Ab was extracted using diethyl acetate
0.4% in 100 mmol/l sodium chloride and the sample was centri-
fuged for 60 min at 100,000g at 4 C (Beckman). The supernatants
were carefully collected and then neutralized by adding 500 mmol/
l Tris–HCl (pH 6.8). Protein quantiﬁcation was performed using the
Bradford method. The levels of soluble Ab40 and Ab42 in rat hippo-
campus extracts were detected using sandwich ELISA kits (Wako,
Japan), according to the manufacturer’s instructions. All samples
were analyzed in duplicate. Concentrations are expressed in pg
per 100 lg of brain tissue.
2.8. Statistical analysis
Data were analyzed using analysis of variance (ANOVA), fol-
lowed by least signiﬁcant difference post hoc tests or independent
samples t tests performed using SPSS 13.0 software (SPSS Inc., IL,
USA). All results are expressed as mean ± standard deviation (S.D.).
3. Results
3.1. Low-dose and medium-dose Ang II as well as SB did not alter rat
SBP
The alterations in SBP caused by continuous Ang II infusion
were tracked in male SD rats by the tail cuff method. Measure-
ments were performed on each of four intermittent days to avoid
depressing the animals. As shown in Fig. 1A, high-dose Ang II treat-
ment was accompanied by signiﬁcantly increased SBP (P < 0.01),
whereas low-dose and medium-dose Ang II caused no statistically
signiﬁcant alteration in SBP (both P > 0.05). Moreover, the baseline
levels of SBP were signiﬁcantly reduced by combined or single
losartan (both P < 0.05) and no signiﬁcant difference between them
was shown (P > 0.05).
Measurements were also performed in SD rats receiving SB
infusion and SHR with or without oral Propranolol. As shown in
Fig. 1B, the increases in SBP by high-dose Ang II and its baselinelevels were not altered by SB (all P > 0.05). As compared to WKY
rats, SHR possessed signiﬁcantly elevated SBPs (Fig. S1, P < 0.01).
After one-week oral administration of 50 or 100 mg/kg Proprano-
lol, the SBPs in SHR were dose-dependently reduced (both
P < 0.01). More reduction was achieved by 50 mg/kg Propranolol
rather than 100 mg/kg Propranolol (P < 0.05).
3.2. High-dose Ang II-induced cognitive impairment was attenuated by
losartan or SB
Cognitive function of rats was herein tested by Morris water
maze and escape latency as well as the time spent in global area
was recorded. As shown in Fig. 2, in rats receiving high-dose Ang
II infusion, escape latency increased while the time spent in global
area declined (all P < 0.01), suggesting that the functions of learn-
ing and memory were impaired. However, no similar alterations
were shown in low-dose and medium-dose Ang II infusion
(P > 0.05). When infusion combined with losartan or SB, high-dose
Ang II-induced cognitive impairment was canceled. However, sin-
gle losartan or single SB caused no alteration in performance.
Swim speed reﬂecting movement function was also recorded.
However, no remarkable difference among all groups was shown,
suggesting that ICV infusion did not interfere in rat movement.
3.3. Hippocampal Ang II levels were elevated by exogenous infusion
Hippocampal distribution of Ang II after ICV infusion was as-
sessed by measurements of Ang II, using commercial enzymatic
immunoassay (EIA) kits. As shown in Fig. S2, the basal levels of hip-
pocampal Ang II in normal rat brains were approximately 55 pg/g.
After one-week infusion of doses of exogenous Ang II, the levels
were increased to 74, 98 and 178 pg/g, respectively. Moreover, its
Fig. 2. High-dose Ang II-induced cognitive impairment was attenuated by losartan or SB. Effects of Ang II, losartan or SB on cognitive performance were assayed by Morris
water maze on day 4–7. Escape latency (A and D), time spent in global area (B and E) and swim speed (C and F) were recorded. All results are presented as mean ± S.D., n = 12
for each group, ⁄⁄P < 0.01 versus the control rats.
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naling as well as SB, the inhibitor of GSK3b.
3.4. Central Ang II signiﬁcantly induced tau phosphorylation
Using commercially available antibodies, the levels of tau phos-
phorylated at different sites could be semi-quantitated by western
blotting analyses. According to a newly recommended protocol
[22], at least ﬁve different sequential detections without losing sig-
niﬁcant amounts of blotted proteins can be achieved, given that
the horseradish peroxidase-conjugated secondary antibody is irre-
versibly inhibited by excess hydrogen peroxide. Therefore, the
ﬁlms presented herein represent blots using antibodies against
tau phosphorylated at speciﬁc sites.
All antibodies used herein were listed in Table 1. As shown in
Fig. 3, after one-week infusion of central Ang II or blockers of its
signaling, the levels of total tau protein (anti-Tau 5 antibody),including unphosphorylated and phosphorylated tau, were not
remarkably changed (P > 0.05, data not shown). In contrast, the
levels of p-tau at six sites were notably increased by one-week
stimulation with central Ang II. Speciﬁcally, a nearly 1.5-fold in-
crease in p-tau at Thr 205 and Ser 356 (both P < 0.05), and at
Thr231, Ser235, Ser396, and Ser404 (all P < 0.01), were achieved
in low-dose and medium-dose Ang II-infused rat brains, compared
with denaturalized Ang II-treated ones (the control group). Fur-
thermore, in high-dose Ang II-treated animals, the increase was ex-
tended to 2.5-fold for p-tau at Thr 205, Ser235, Ser 356, Ser396 and
Ser404, and to approximately 3-fold in p-tau at Thr231 (all
P < 0.01).
However, some slight but not statistically signiﬁcant alterations
in the levels of p-tau were found when Ang II was administered in
combination with losartan (P > 0.05). Because losartan exerts
speciﬁc blockade of AT1R, the results herein conﬁrmed the involve-
ment of AT1R in central Ang II-induced tau phosphorylation.
Fig. 3. Central Ang II infusion signiﬁcantly induced tau phosphorylation. The hippocampal levels of tau phosphorylated at six sites were measured by western blotting and
subsequent quantitative analysis. (A) Representative enhanced chemiluminescence radiographs of immunoblots showing tau phosphorylated at various sites. Density
analysis showing levels of tau phosphorylated at Thr205 (B), Thr231 (C), Ser235 (D), Ser356 (E), Ser396 (F), and Ser404 (G). Data in (B–G) were normalized to the level of total
tau (anti-tau 5), whereas the intensity of tau 5 was normalized to the level of b actin. All data are represented as mean ± S.D., n = 12 for each group, ⁄P < 0.05 or ⁄⁄P < 0.01
versus the control group.
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Because the action of GSK 3b is regulated by activity-dependent
phosphorylation at Tyr216, the activity of GSK 3b is represented by
the levels of phosphorylated GSK 3 b (Fig. 4A and B). After a one-
week Ang II infusion, the levels of p-Tyr216-GSK 3b was signiﬁ-
cantly unregulated (P < 0.05 or 0.01), suggesting the activation of
GSK 3b. However, when normalized to the levels of b actin, the lev-
els of total GSK 3 were not affected (P > 0.05, data not shown). The
alterations in GSK 3bwere all prevented by a combination of Ang II
with losartan (P > 0.05), suggesting that activation of GSK 3b is de-
rived from stimulated AT1Rs.
3.6. Activated GSK 3b in SHR hippocampus was attenuated by
Propranolol
In hippocampus of SHR, a genetic hypertensive model, the
levels of p-Tyr216-GSK 3b were also signiﬁcantly elevated, as
compared to its normotensive control, the WKY rat (Fig. 4C and
D). Then, the increases were attenuated by daily administration
of 50 or 100 mg/kg Propranolol (P < 0.01), a non-RAS inhibitoranti-hypertensive drug. However, as compared to 50 mg/kg
Propranolol, a rebound increase was shown in 100 mg/kg Propran-
olol (P < 0.05).
3.7. A GSK 3b inhibitor attenuated Ang II-induced tau phosphorylation,
but didn’t alter Ab production
SB216763 (SB) has been widely accepted as an inhibitor of GSK
3b. When 20 ng/ll SB was co-administered with high-dose Ang II,
the levels of p-tau at six sites were signiﬁcantly attenuated
(P < 0.01 or 0.05, Fig. 5), compared with animals receiving high-
dose Ang II. However, compared with the control group, only the
levels of p-tau at Ser 356 were normalized to the basal level
(P > 0.05). However, high-dose Ang II-induced Ab (including Ab40
and Ab42) production was not altered by SB, and single SB infusion
was not accompanied with Ab production (Fig. 6).
4. Discussion
According to the vascular hypothesis, AD is triggered by
progressing vascular abnormalities [2], and vascular risk factor
Fig. 4. The activation of GSK3bwas promoted by central Ang II and hypertension. The activity of GSK3b is represented by the levels of the active form of GSK 3b (pGSK3b-Tyr
216), using western blotting. (A and C) Representative immunoblots showing the immunoreactivity for total and phosphorylated GSK3b. (B and D) quantitative analysis of the
levels of phosphorylated GSK3b. The levels of total GSK 3b were normalized to those of b actin (data not shown) and the levels of phosphorylated GSK 3bwere normalized to
those of total GSK 3b. All data are represented as mean ± S.D., n = 12 for each group, ⁄⁄P < 0.01 versus the control group or the WKY rats, ##P < 0.01 versus the high-dose Ang II
group, &P < 0.05 versus the 50 mg/kg Propranolol group.
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dozen heterogeneous vascular risk factors for AD have been re-
ported, including ischemic stroke, atherosclerosis, hypertension,
diabetes and cardiac disease [24]. Mild but persistent vascular le-
sions are associated with serial sequential events, including Ab
upregulation or deposition [25,26]. Moreover, recent evidence
has documented that the toxicity of Ab and the severity of AD is
dependent on elevated p-tau [1], suggesting the necessity of p-
tau in AD pathogenesis.
The RAS, one of the most important cardiovascular manage-
ment systems, has been implicated in AD [27]. Ang II, the principal
mediator of the RAS, acts as an ampliﬁer of cardiovascular risk,
mainly through AT1R [28]. Moreover, the use of RAS blockers in
animal models or human beings affected by AD or at risk for AD
was linked to reduced AD incidence, attenuated neurotoxic pathol-
ogy or rescued cognitive impairment. In our laboratory, central Ang
II stimulation promoted brain Ab production in normal rodents,
and this was canceled by AT1R blockers [13]. However, the levels
of p-tau were not assayed, despite being of crucial importance in
Ab neurotoxicity and subsequent AD-related neurodegeneration.
In the present study, graded doses of Ang II were delivered con-
tinuously into rat brain ventricles via osmotic pumps. Although
Ang II acts as a pressor peptide, ICV administration of low- or med-
ium-dose Ang II caused no remarkable increases in SBP, whereas
high-dose Ang II did (Fig. 1A). This suggested that central Ang II-in-
duced pressor effects are dose-dependent. The increases in SBP by
high-dose Ang II were then canceled by losartan. Moreover, no sta-
tistical signiﬁcance was shown between combined and single
losartan, inferring that anti-hypertensive effects of losartan are
not dependent on Ang II.
We then assayed the cognitive performance of rats using Morris
water maze. Similar to alterations in SBP, cognitive impairment
was induced only by high-dose Ang II and prevented by losartan
(Fig. 2A and B). However, when combined with SB, a speciﬁc GSK
3b inhibitor, high-dose Ang II-induced cognitive impairment was
also prevented without decline in SBP (Figs. 1B, 2D and E).Therefore, these ﬁndings suggested that the impairment by Ang
II was not dependent on blood pressure. As noted herein, no move-
ment dysfunction was induced by Ang II (Fig. 2C and F).
Hippocampus is crucial to cognition. In the present study, hip-
pocampal levels of Ang II after one-week infusion were assayed
by EIA. As expected, hippocampal Ang II contents were remarkably
elevated by doses of exogenous Ang II. It may be due to simple dif-
fusion and enhanced synthesis by itself. Interestingly, losartan, the
blocker of Ang II signaling, caused no alteration in Ang II distribu-
tion, although abundant AT1R was localized in hippocampus [29].
Similar results were shown in Ang II + SB animals, suggesting that
the GSK3b signaling was not involved in Ang II levels.
Although tau phosphorylation was also crucial to many physio-
logical processes including axonal growth [30], phosphorylation at
certain sites was involved in AD pathogenesis. Among the 85 puta-
tive phosphorylation sites in tau, tau phosphorylated at six repre-
sentative sites accumulates in AD brains [31], and these sites were
selected for analysis herein. As shown in Fig. 3, the levels of p-tau
at these six sites were dose-dependently elevated after one-week
Ang II infusion, although the levels of total tau were not altered.
Moreover, signiﬁcant tau phosphorylation was induced by low-
and medium-dose Ang II without detected cognitive impairment.
This implied that pathological alteration preceded visible pheno-
types in AD, which was in accordance with previous reports [30].
Then, Ang II-induced tau phosphorylation was signiﬁcantly atten-
uated by blockade of AT1R, suggesting that Ang II-induced tau
phosphorylation is AT1R-mediated. As noted, losartan can also
block the endogenous Ang II signaling, which may contribute to
the slight decrease in single losartan-treated rats herein (Fig. 3).
However, due to complicated regulatory network or alternative
complementary mechanisms in body, the basal p-tau levels were
not signiﬁcantly altered.
GSK3b, a proline-directed serine-threonine kinase, has been
identiﬁed as the main tau kinase [32]. Its expression and activity
is induced in AD brains [33]. Interestingly, the actions of GSK3b
are also phosphorylation dependent. It can be activated by
Fig. 5. A GSK 3b inhibitor attenuated Ang II-induced tau phosphorylation. Ang II was delivered into rat brains in combination with SB, a widely-studied GSK 3 inhibitor. (A)
Representative immunoblots showing tau phosphorylated at various sites. Density analysis showing the levels of tau phosphorylated at Thr205 (B), Thr231 (C), Ser235 (D),
Ser356 (E), Ser396 (F), and Ser404 (G). Data in (B–G) were normalized to total tau (anti-Tau 5), whereas the intensity of Tau 5 was normalized to that of b actin (data not
shown). All data are represented as mean ± S.D., n = 12 for each group, ⁄P < 0.05 or ⁄⁄P < 0.01 versus the control group. #P < 0.05 or ##P < 0.01 versus high-dose Ang II-infused
group.
Fig. 6. Ang II-induced Ab production was not altered by the GSK3b inhibitor, SB. Hippocampal Ab levels were measured in the high-dose Ang II group with or without SB,
using sandwich ELISA. Assays in Ab40 (A) and Ab42 (B) were performed in duplicate. All data are represented as mean ± S.D., n = 12 for each group, ⁄P < 0.05 or ⁄⁄P < 0.01
versus the control group.
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Fig. 4, despite no change in the levels of total GSK3b after continu-
ous Ang II stimulation, the levels of p-Tyr 216-GSK3b were signif-
icantly elevated. However, these alterations were canceled by
losartan, suggesting that the expression of GSK3b and its activities
can be upregulated by Ang II binding to AT1R. As noted, brain GSK
3b phosphorylation can be also induced by Ab [35]. Therefore, the
elevated production of Ab-induced by Ang II, as conﬁrmed in our
previous studies, could be an important mediator of Ang II-induced
tau phosphorylation, which is now being investigated using Ab
immunization in our laboratory.
As noted herein, the activities of GSK 3b were increased by
Ang II but reduced by losartan, accompanied with alterations in
SBP. We then investigated the roles of blood pressure in GSK 3b
activation using a genetic hypertensive model, SHR. Since Ang II
exerts many effects unrelated to its pressor action, doses of a
non-RAS inhibitor anti-hypertensive drug, Propranolol, were oral-
ly administrated to SHR. Elevated SBPs in SHR were conﬁrmed by
the tail cuff method (Fig. S1), while unregulated p-Tyr 216-GSK3b
levels were also shown in SHR hippocampus. The SBPs in SHR
were reduced by daily Propranolol, accompanied by attenuated
GSK 3b activation. However, more signiﬁcant decrease in GSK
3b activities was achieved in 50 mg/kg although lower SBP was
shown in 100 mg/kg. These ﬁndings suggested that hypertension
is an important but not the only signaling in Ang II-induced GSK
3b activation.
Some other kinases, including cyclin-dependent kinase 5, casein
kinase 1, protein kinase A and mitogen-activated protein kinases
(MAPKs) have been implicated in tau phosphorylation [36] and
in neuronal Ang II signaling [37]. The involvement of GSK3b in
the Ang II-induced tau phosphorylation observed herein was con-
ﬁrmed using SB, a widely-studied inhibitor speciﬁc for GSK3b. As
expected, the phosphorylation of all sites induced by central Ang
II was signiﬁcantly attenuated by inhibition of GSK3b. P-tau at
Ser356 was normalized to the basal level by SB, implying that
the dose of SB used herein was sufﬁcient. However, phosphoryla-
tion at other sites was not blocked to the same extent. This incon-
sistency suggested that GSK3b might phosphorylate tau at speciﬁc
sites only, and that it may not be the only kinase mediating Ang II-
induced tau phosphorylation. Further studies are thus warranted
to elucidate the roles of other kinases, for example, MAPKs, in
Ang II-induced tau phosphorylation.
Ab production was also stimulated by Ang II in our previous
studies [13]. The role of the GSK3b signaling in Ang II-induced Ab
production was thus investigated herein. As shown in Fig. 6, inhi-
bition of GSK3b by SB didn’t alter the levels of Ab-induced by high-
dose Ang II. This is in accordance with a recent study, in which
in vivo Ab production was not controlled by GSK 3b [38].
Taken together, these ﬁndings suggested that Ang II, the crucial
mediator of cardiovascular pathology, induced signiﬁcant cognitive
impairment and signiﬁcant tau phosphorylation via activating
GSK3b and other kinases. Attenuated tau phosphorylation pro-
tected against cognitive impairment, conﬁrmed the crucial role of
p-tau in AD pathogenesis. Given the roles of Ang II in cardiovascu-
lar events, these ﬁndings combined with our previous report will
promote the establishment of the Ang II-Ab-GSK3b-tau cascade,
and provide evidences for the vascular origin of AD pathogenesis.
Since the blood–brain carrier is permeable to most AT1R blockers
including losartan, blockade of brain Ang II signaling represents a
promising strategy for anti-AD therapies.
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